1,951 reports of this reaction
1.8% of all CYTARABINE reports
#12 most reported adverse reaction
MYELOSUPPRESSION is the #12 most commonly reported adverse reaction for CYTARABINE, manufactured by Fresenius Kabi USA, LLC. There are 1,951 FDA adverse event reports linking CYTARABINE to MYELOSUPPRESSION. This represents approximately 1.8% of all 108,092 adverse event reports for this drug.
Patients taking CYTARABINE who experience myelosuppression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELOSUPPRESSION is a less commonly reported adverse event for CYTARABINE, but still significant enough to appear in the safety profile.
In addition to myelosuppression, the following adverse reactions have been reported for CYTARABINE:
The following drugs have also been linked to myelosuppression in FDA adverse event reports:
MYELOSUPPRESSION has been reported as an adverse event in 1,951 FDA reports for CYTARABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELOSUPPRESSION accounts for approximately 1.8% of all adverse event reports for CYTARABINE, making it a notable side effect.
If you experience myelosuppression while taking CYTARABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.